Healthcare systems

Formal recognition of type 2 diabetes remission in primary care may lead to suboptimal health monitoring, a study suggests.

Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Researchers find that a single questionnaire item assessing vitality predicts major adverse cardiovascular events in people with type 2 diabetes.

Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.

Clinical complexity and treatment burden have both increased over recent years among people with diabetes in the USA, say researchers.

The disruption of routine diabetes care during the pandemic may have resulted in an increased risk for mortality from causes not linked to COVID-19, research suggests.

The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.